Gain Therapeutics, Inc. (GANX) Social Stream
GAIN THERAPEUTICS INC (GANX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering GANX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-09 | 4 | $30 | $21 | $27 | $2.77 | 874.73% |
| 2022-04-01 | 4 | $30 | $12 | $22 | $2.77 | 694.22% |
| 2022-04-13 | 3 | $30 | $12 | $19.333 | $2.77 | 597.94% |
| 2022-08-15 | 3 | $30 | $11 | $17.666 | $2.77 | 537.76% |
| 2022-08-26 | 3 | $30 | $5 | $15.666 | $2.77 | 465.56% |
| 2022-11-14 | 4 | $30 | $5 | $13.75 | $2.77 | 396.39% |
| 2022-11-25 | 5 | $10 | $5 | $8.75 | $2.77 | 215.88% |
| 2022-12-11 | 4 | $10 | $4 | $8.5 | $2.77 | 206.86% |
| 2022-12-16 | 5 | $10 | $4 | $7.8 | $2.77 | 181.59% |
| 2023-05-15 | 4 | $10 | $5.75 | $8.937 | $2.77 | 222.64% |
| 2023-08-31 | 4 | $10 | $6 | $9 | $2.77 | 224.91% |
| 2023-10-02 | 5 | $10 | $6 | $9.2 | $2.77 | 232.13% |
| 2023-11-17 | 5 | $10 | $6 | $9 | $2.77 | 224.91% |
| 2023-12-01 | 5 | $10 | $6 | $8.75 | $2.77 | 215.88% |
| 2023-12-04 | 5 | $10 | $6 | $8.5 | $2.77 | 206.86% |
The Trend in the Analyst Price Target
GANX's average price target has moved down $10.83 over the prior 20 months.
Over the past 36 weeks, GANX's average upside potential has been 155.92%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-01 | 4 | 10 | 5.75 | 8.937 | 5.23 | 70.88% |
| 2023-08-31 | 5 | 10 | 6.00 | 9.000 | 3.31 | 171.9% |
| 2023-08-31 | 4 | 10 | 6.00 | 9.000 | 3.31 | 171.9% |
| 2023-10-02 | 5 | 10 | 6.00 | 9.200 | 3.27 | 181.35% |
| 2023-11-17 | 5 | 10 | 6.00 | 9.000 | 2.70 | 233.33% |
GANX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 122 days, GANX's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for GANX as an investment opportunity.
- In the context of all US stocks, GAIN THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1741.17% of them.
- In terms of how GAIN THERAPEUTICS INC fares relative to all US stocks, note that its number of analysts covering the stock is higher than 272.34% of that group.
- GAIN THERAPEUTICS INC's average analyst price target is higher than 309.84% of all US stocks.
- GAIN THERAPEUTICS INC's variance in analysts' estimates is lower than -1348.93% of stocks in the micro market cap category.
In the Pharmaceutical Products industry, UPC, RPHM, and ANEB are the three stocks most similar to GAIN THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for GANX? Use POWR Ratings for clearer insight into price direction.